跳转至内容
Merck
CN

M-144

Supelco

MDAI hydrochloride solution

100 μg/mL in acetonitrile: water (9:1) with 5% 1 M HCl (as free base), ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价

关于此项目

经验公式（希尔记法）:
C10H11NO2 · HCl
CAS Number:
155344-90-4
分子量:
213.66
UNSPSC代码:
41116107
NACRES:
NA.24

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

certified reference material

质量水平

300

表单

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

drug control

Narcotic Licence Schedule E (Switzerland); Pszichotróp anyag / Psychotropic Substance (Hungary), 78/2022. (XII. 28.) BM rendelet

浓度

100 μg/mL in acetonitrile: water (9:1) with 5% 1 M HCl (as free base)

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

forensics and toxicology

包装形式

single component solution

储存温度

−70°C

SMILES字符串

Cl.NC1Cc2cc3OCOc3cc2C1

InChI

1S/C10H11NO2.ClH/c11-8-1-6-3-9-10(13-5-12-9)4-7(6)2-8;/h3-4,8H,1-2,5,11H2;1H

InChI key

DEZYWEZDXRXACY-UHFFFAOYSA-N

一般描述

MDAI, or 5,6-Methylenedioxy-2-aminoindane, is a new stimulant and club/designer drug with significant cases of abuse reported in Asia, Europe and the US. Sold over the Internet as a “bath salt,” MDAI is a potential successor to mephedrone as the next legal high drug.

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

象形图

FlameExclamation mark
GHS02,GHS07

警示用语：

Danger

危险分类

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

储存分类代码

3 - Flammable liquids

WGK

WGK 2

闪点(°F)

55.4 °F - closed cup

闪点(°C)

13 °C - closed cup

法规信息

监管及禁止进口产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Roland P Archer et al.
Drug testing and analysis, 3(7-8), 505-514 (2011-07-12)
Historically, the appearance of new psychoactive materials (and hence the requirement for new reference standards) has been relatively slow. This position has now changed, with 101 new psychoactive substances reported to EMCDDA-Europol since 2006. The newly reported materials, and associated
Cathal T Gallagher et al.
Human psychopharmacology, 27(2), 106-112 (2012-03-06)
The fully synthetic 'legal high' 5,6-methylenedioxy-2-aminoindane (MDAI) is an analogue of 3,4-methylenedioxymethamphetamine. Although developed in the 1990s, it was not widely abused until 2010. However, mephedrone was banned in the UK in April 2010, and almost immediately, MDAI was widely
R Oberlender et al.
The Journal of pharmacology and experimental therapeutics, 255(3), 1098-1106 (1990-12-01)
The stimulus properties of 3,4-methylenedioxymethamphetamine (MDMA)-like compounds were studied in rats trained to discriminate saline from (+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine [(+)-MBDB] hydrochloride (7.18 mumol/kg; 1.75 mg/kg), the alpha-ethyl homolog of MDMA. In previous experiments with (+)-MBDB as a test drug, complete substitution was
Laurent Karila et al.
Drug testing and analysis, 3(9), 552-559 (2011-10-01)
Designer drugs belong to a group of legally or illegally produced substances that are structurally and pharmacologically very similar to illicit drugs. In the past, designer drugs were often used during all-night dance parties, but they are now consumed in
M P Johnson et al.
Pharmacology, biochemistry, and behavior, 40(4), 915-922 (1991-12-01)
There is increasing evidence linking dopamine (DA) to the long-term serotonergic (5-HT) neurotoxic effects of certain substituted amphetamines such as 3,4-methylenedioxymethamphetamine (MDMA). The present study was undertaken to examine the importance of DA metabolism, uptake inhibition and release in the
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持